- Details
- Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in oligometastatic castration-sensitive prostate cancer. The conversation explores validation studies demonstrating the test's prognostic value for overall survival and its potential to predict benefit from metastasis-directed therapy using data from the STOMP and ORIOLE trials. The...
|
- Details
- Alicia Morgans interviews Andre Esteva about ArteraAI's expanded prostate cancer test, now validated for low-risk and active surveillance patients. Dr. Esteva explains that the AI-driven test helps clinicians decide between active surveillance and definitive treatment by assessing the risk of adverse pathology at prostatectomy. The test, which uses digital pathology to analyze H&E slides without c...
|
- Details
- Zach Klaassen interviews Karen Hoffman about the PROSTATE-IQ trial, which aims to reduce the burden of androgen deprivation therapy (ADT) in men receiving salvage radiotherapy for prostate cancer. The trial incorporates the ArteraAI Prostate Test to stratify patients and explores alternative treatment strategies, including the use of apalutamide. Dr. Hoffman explains that the study focuses on impr...
|
- Details
- Zach Klaassen speaks with Mark Markowski about the advancements in AI, particularly the ArteraAI Prostate Test, and its implications for prostate cancer treatment. Dr. Markowski explains how ArteraAI has evolved from predicting treatment responses in localized prostate cancer to potentially guiding treatment decisions in metastatic hormone-sensitive prostate cancer. The CHAARTED study, a pivotal t...
|
- Details
- Zach Klaassen speaks with Todd Morgan about innovative approaches in the management of prostate cancer post-prostatectomy. Dr. Morgan presents compelling new data on the prostate AI test, highlighting its use in identifying biochemical recurrence after prostatectomy. This AI model, validated with data from key trials, not only distinguishes patients based on the aggressiveness of their disease but...
|
- Details
- Zach Klaassen discusses with Todd Morgan about innovative post-prostatectomy biomarkers. Dr. Morgan presents findings on a new AI model developed by ArteraAI for assessing biochemical recurrence in prostate cancer patients post-prostatectomy. This model, validated using clinical data and digital pathology from two significant trials, shows high predictive accuracy. It aims to distinguish patients...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the emergence of the ArteraAI Prostate Test for risk stratification in prostate cancer management. This innovative test, now considered a predictive model, marks a significant advance, providing more accurate risk assessments for biochemical recurrence, distant metastasis, and prostate can...
|
- Details
- Alicia Morgans interviews Gerhardt Attard about groundbreaking research presented at ESMO 2023, utilizing the STAMPEDE data set. They discuss a new prognostic tool developed with Artera, the ArteraAI Prostate Score, which predicts prostate cancer-specific mortality using digitized images of H&E slides from over 3,300 patients. This tool has proven that primary tumor analysis can provide significan...
|
- Details
- Dan Spratt joins Alicia Morgans in a conversation on the Artera AI multimodal artificial intelligence model manuscript published in the NEJM Evidence. The Artera predictive model for prostate cancer is a significant advancement in personalized medicine for patients with localized prostate cancer. Unlike prognostic biomarkers that help identify patients at lower or higher risk of developing recurre...
|
- Details
- In a discussion with Alicia Morgans, Paul Nguyen highlights the advancing role of predictive biomarkers in prostate cancer treatment. He distinguishes between prognostic and predictive biomarkers, emphasizing the unique value of the latter in tailoring the right amount of treatment for individual patients. They focus on the development of a commercial test by Artera that predicts responses to shor...
|
